Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Multicenter retrospective analysis of 114 RRMM pts txd w/ talquetamab finds ORR 73%, CR 26% and VGPR in 26%, 6-month PFS and OS of 56 and 86%; common AEs included CRS (54% with grade ≥2), infections (27%), and ICANS (9.8%).”
Title: Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Authors: Samer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, Aishee Bag, Simon Zhen, Yetunde Ogunsesan, Evanka Annyapu, Binod Dhakal, Divaya Bhutani, Sharmilan Thanendrarajan, Maurizio Zangari, Anita D’Souza, Suzanne Lentzsch, Frits van Rhee, Rajshekhar Chakraborty, Carolina Schinke, Meera Mohan, Mansi R. Shah
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
